We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SPGI:NYSES&P Global Inc. Analysis

Data as of 2026-05-27 - not real-time

$414.95

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

S&P Global (SPGI) is trading at $414.95, well above its DCF‑derived fair value of $320.76 and its 20‑day SMA of $418.79, indicating a short‑term overextension. The 14‑day RSI sits at 45.4, suggesting neutral momentum, while the MACD histogram has turned marginally positive, hinting at a tentative bullish signal amid an overall bearish trend. Valuation metrics are stretched: the forward PE of 18.7 is still above the industry average PE of 16.6, and the price‑to‑book of 3.94 exceeds the sector norm. Volatility remains elevated at 22.5% over the past 30 days, though beta is low at 0.50, reflecting limited systematic risk. Fundamentally, the company delivers robust performance with 10.4% revenue growth, a 70.5% gross margin, and a 44.3% operating margin, supported by strong free cash flow of $5.30 bn and a modest payout ratio of 24%. Recent material news highlights a $2 bn private senior notes offering and a $2.5 bn financing round ahead of a planned spinoff, providing potential upside catalysts. The dividend of $0.97 (0.94% yield) remains sustainable given the healthy cash flow and low payout. Taken together, the stock appears overvalued in the near term but possesses strong underlying fundamentals and dividend appeal for longer horizons.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price trading above short‑term moving averages
  • Neutral RSI and marginal MACD bullishness
  • Overvaluation relative to DCF and peers

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth and high profit margins
  • Sustainable dividend with low payout ratio
  • Potential catalyst from new financing and upcoming spinoff

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Durable competitive moat in financial data and ratings
  • Consistent free cash flow generation
  • Attractive dividend yield for income‑focused investors

Key Metrics & Analysis

Financial Health

Revenue Growth10.40%
Profit Margin30.36%
P/E Ratio26.3
ROE13.94%
ROA6.92%
Debt/Equity38.39
P/B Ratio3.9
Op. Cash Flow$5.7B
Free Cash Flow$5.3B
Industry P/E16.6

Technical Analysis

TrendBearish
RSI45.4
Support$401.00
Resistance$438.88
MA 20$418.79
MA 50$424.83
MA 200$479.50
MACDBullish
VolumeIncreasing
Fear & Greed Index91.93

Valuation

Fair Value$320.76
Target Price$533.76
Upside/Downside28.63%
GradeOvervalued
TypeGrowth
Dividend Yield0.94%

Risk Assessment

Beta0.50
Volatility22.54%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.